List of Excipients in Branded Drug LOMOTIL

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Pfizer Laboratories Div Pfizer Inc	LOMOTIL	diphenoxylate hydrochloride and atropine sulfate	0025-0061	ACACIA
Pfizer Laboratories Div Pfizer Inc	LOMOTIL	diphenoxylate hydrochloride and atropine sulfate	0025-0061	MAGNESIUM STEARATE
Pfizer Laboratories Div Pfizer Inc	LOMOTIL	diphenoxylate hydrochloride and atropine sulfate	0025-0061	SORBITOL
Pfizer Laboratories Div Pfizer Inc	LOMOTIL	diphenoxylate hydrochloride and atropine sulfate	0025-0061	STARCH, CORN
Pfizer Laboratories Div Pfizer Inc	LOMOTIL	diphenoxylate hydrochloride and atropine sulfate	0025-0061	SUCROSE
Pfizer Laboratories Div Pfizer Inc	LOMOTIL	diphenoxylate hydrochloride and atropine sulfate	0025-0061	TALC

LOMOTIL Excipient Strategy and Commercial Opportunities

Last updated: August 14, 2026

LOMOTIL contains diphenoxylate hydrochloride and atropine sulfate for symptomatic treatment of acute and chronic diarrhea. Its core formulation is mature, inexpensive, and broadly substitutable. The strongest commercial opportunities are therefore not based on new chemical entity protection. They are based on excipient differentiation, pediatric acceptability, abuse-deterrent presentation, improved stability, global formulation adaptation, and reliable generic supply.

The principal formulation constraints are taste, dose uniformity at low atropine loading, alcohol and sugar content, preservative exposure, moisture control, and safe dosing in children. A successful product must preserve bioequivalence while improving usability, manufacturing economics, and channel access.

What is the active ingredient and dosage-form profile of LOMOTIL?

LOMOTIL combines two active ingredients:

Component	Function	Reference strength
Diphenoxylate hydrochloride	Peripheral opioid antidiarrheal	2.5 mg per tablet
Atropine sulfate	Included in a subtherapeutic amount to discourage deliberate overuse	0.025 mg per tablet

The product is marketed primarily as an oral tablet and oral liquid. The liquid strength is commonly expressed as 2.5 mg diphenoxylate hydrochloride and 0.025 mg atropine sulfate per 5 mL, matching the tablet ratio.[1]

Diphenoxylate is a Schedule V controlled substance in the United States when combined with atropine. The control status affects packaging, distribution, recordkeeping, diversion controls, and product positioning.[2]

What are the principal inactive ingredients in LOMOTIL?

Reference formulations have used conventional oral solid and liquid excipients. Depending on the presentation and manufacturer, relevant excipient classes include:

• Lactose or another diluent
• Microcrystalline cellulose
• Starch or pregelatinized starch
• Dibasic calcium phosphate
• Magnesium stearate
• Suspending and thickening agents in oral liquids
• Sweeteners, flavors, and preservatives in liquid products
• Purified water as the liquid vehicle

The exact inactive-ingredient composition must be confirmed against the current FDA labeling and product-specific filing. FDA’s Inactive Ingredient Database is the principal regulatory reference for determining prior use by route, dosage form, and maximum daily exposure.[3]

What excipient strategy best fits a LOMOTIL generic?

A commercially viable strategy should begin with a conservative bioequivalent tablet and then develop differentiated presentations in separate programs. A single formulation should not be forced to serve adult, pediatric, hospital, and international markets.

Strategy 1: Match the reference tablet with a low-risk excipient system

The first product should use familiar, compendial excipients with established oral-tablet precedent. A conventional direct-compression or wet-granulation system can reduce development risk.

The formulation priorities are:

1. Assay and content uniformity for the very low atropine dose.
2. Rapid and reproducible dissolution.
3. Low tablet weight and acceptable hardness.
4. Low friability during controlled-substance distribution.
5. Stability under high-temperature and high-humidity conditions.
6. Compatibility with unit-dose blister or bottle packaging.

Atropine represents only a small fraction of the active load. The formulation must prevent segregation during blending and compression. Ordered mixing, geometric dilution, carrier-based premixes, or granulation can improve uniformity. Analytical methods should measure diphenoxylate and atropine independently because a formulation may meet total active content while showing weak atropine distribution.

A simple lactose-cellulose-starch system may be cost-effective, but lactose intolerance claims, global labeling requirements, and patient preferences can support a lactose-free alternative. Calcium phosphate can improve tablet robustness but may affect flow, density, and dissolution behavior. Magnesium stearate should be controlled tightly because over-lubrication can slow wetting and dissolution.

Strategy 2: Develop a sugar-free, alcohol-free oral liquid

The oral liquid has the clearest excipient-led differentiation opportunity. Patients with acute diarrhea often include children, older adults, and individuals with diabetes or swallowing limitations.

A preferred platform would use:

• A sugar-free sweetener system
• A low-viscosity suspending agent
• A flavor system that masks diphenoxylate bitterness
• A preservative system compatible with pH and packaging
• An alcohol-free vehicle
• A calibrated oral syringe rather than a household teaspoon

Potential sweetener systems include sorbitol, sucralose, acesulfame potassium, or combinations. Polyols can improve mouthfeel but may cause gastrointestinal discomfort at higher exposures. High-intensity sweeteners reduce osmotic load but can leave aftertaste.

Suspension stability is a major technical issue. The product must redisperse readily after storage without producing a concentrated first dose or a weak final dose. Xanthan gum, hydroxyethylcellulose, sodium carboxymethylcellulose, and microcrystalline cellulose-carboxymethylcellulose systems are potential platforms, subject to compatibility and prior-use review.

The formulation should target a short shake-to-uniformity time. Excessive viscosity increases dosing errors and makes the product difficult to withdraw through an oral syringe. A bottle-and-syringe system can be positioned as a pediatric and caregiver product, but the device becomes part of the regulatory and commercial package.

Strategy 3: Use taste masking as the primary product differentiator

Diphenoxylate-containing liquids can have an unpleasant taste. Taste masking can improve adherence more effectively than minor changes in viscosity or color.

Relevant approaches include:

• Flavor and sweetener optimization
• Ion-exchange resin complexation
• Polymer coating of drug particles
• Microencapsulation
• Multiparticulate suspension
• pH adjustment within stability and tolerability limits
• Cyclodextrin or other complexation systems where justified

A coated or encapsulated system may create a stronger product profile, but it increases development complexity. The sponsor must demonstrate that taste masking does not alter dissolution, absorption, dose uniformity, or storage stability. A complexed or coated active may also raise manufacturing and control costs.

For a standard ANDA, simple flavor optimization is lower risk. A novel taste-masked system is more suitable for a 505(b)(2) strategy if it provides a clinically meaningful administration advantage and the regulatory pathway supports reliance on the reference product.[4]

What formulation patents could protect a new LOMOTIL product?

Legacy LOMOTIL composition patents are unlikely to provide a meaningful current barrier to generic development. The commercial value lies in newly developed formulation, device, manufacturing, or packaging claims.

Potential patentable subject matter includes:

Area	Possible claim focus	Commercial relevance
Taste masking	Coated particles or resin complexes	Supports pediatric and adherence positioning
Oral liquid	Preservative-free or alcohol-free suspension	Differentiates from conventional liquids
Suspension stability	Redispersion, sedimentation, particle-size control	Reduces dose variability
Dose delivery	Bottle adapter, oral syringe, unit-dose cup	Improves caregiver use
Abuse deterrence	Packaging, dose limitation, controlled dispensing	Supports controlled-substance risk management
Manufacturing	Uniform atropine premix or granulation process	Protects low-dose content uniformity
Packaging	Moisture-resistant unit-dose presentation	Improves stability and institutional use
Alternate dosage form	ODT, chewable, multiparticulate, or sprinkle product	Expands swallowing-limited populations

Patent strength will depend on claim breadth and design-around exposure. A narrow claim covering one flavor, one polymer concentration, or one viscosity range is usually weak commercially. Stronger protection would connect the excipient system to measurable performance, such as taste threshold, redispersion time, dissolution profile, or atropine content uniformity.

A sponsor should not assume that an excipient combination is patentable merely because it is new to the product. Unexpected technical effects and reproducible performance data are usually required to support enforceable claims.

What is the FDA regulatory status and Orange Book position of LOMOTIL?

LOMOTIL is an FDA-approved prescription product containing diphenoxylate hydrochloride and atropine sulfate. The reference product is associated with FDA-approved labeling for oral tablets and oral solution.[1]

An ANDA applicant can generally seek approval by demonstrating pharmaceutical equivalence and bioequivalence to the listed reference product. A materially different dosage form, route, composition, or administration benefit may require a 505(b)(2) application rather than a conventional ANDA.[4]

The relevant regulatory checks are:

• Current Drugs@FDA listing for the reference NDA
• Current Orange Book reference-product designation
• Listed patents and regulatory exclusivities
• Controlled-substance requirements
• Product-specific guidance, if issued
• Inactive Ingredient Database precedents
• FDA-approved labeling and dosage instructions

The legacy product does not have a commercially significant new-drug exclusivity period. No biosimilar pathway applies because LOMOTIL is a small-molecule drug, not a biologic. The main regulatory barrier is therefore approval of a compliant generic or differentiated formulation, not loss of biologic exclusivity.[5]

When does LOMOTIL lose exclusivity?

LOMOTIL’s original small-molecule exclusivity and legacy patent protection have expired. Generic competition is already established. The economic question is not the date of first generic entry but whether a new formulation can obtain approval and earn a price premium.

Any current Orange Book patent listing must be reviewed in the live FDA database before filing or launch. For a mature product, residual risks usually arise from product-specific patents, formulation patents, labeling restrictions, controlled-substance requirements, or manufacturing disputes rather than core active-ingredient protection.

Which companies are challenging or competing with LOMOTIL?

LOMOTIL competes with both prescription and nonprescription antidiarrheal products.

Competitive group	Examples	Competitive effect
Diphenoxylate-atropine generics	Multiple ANDA manufacturers	Direct price competition
Loperamide products	IMODIUM and generic loperamide	Strong OTC substitution
Bismuth products	Bismuth subsalicylate products	OTC alternative for selected indications
Oral rehydration products	Electrolyte solutions	Compete for first-line supportive treatment
Specialty gastrointestinal products	Disease-specific therapies	Limit use in inflammatory, infectious, or functional disease settings

Loperamide is the most important direct commercial comparator because it is widely available without a prescription and has multiple tablet, capsule, liquid, and chewable presentations. A LOMOTIL product must therefore compete on prescriber familiarity, controlled prescription access, liquid dosing, institutional procurement, or targeted patient populations.

The product should not be positioned as interchangeable with every antidiarrheal. The FDA label warns against use in certain infectious and inflammatory conditions and emphasizes hydration and monitoring.[1] Commercial materials must remain consistent with approved labeling.

What commercial opportunities exist for LOMOTIL excipient innovation?

Pediatric liquid and caregiver-focused packaging

A well-tolerated, sugar-free suspension with an oral syringe offers the clearest product opportunity. The target customers include pediatric prescribers, caregivers, hospitals, and specialty pharmacies.

The value proposition is practical:

• Easier administration
• Better taste
• More accurate measurement
• Lower sugar exposure
• No alcohol in the vehicle
• Improved portability and storage

Pediatric positioning requires careful safety review because atropine-containing diphenoxylate products have age-related restrictions and opioid-related risks. The formulation cannot be marketed broadly to children unless the approved labeling supports that use.

Institutional and hospital unit-dose formats

Hospitals, long-term-care facilities, correctional systems, and emergency departments may value unit-dose packaging. A blister or foil pouch can improve controlled-substance accountability and reduce medication waste.

Unit-dose packaging also supports:

• Barcode administration
• Tamper evidence
• Inventory reconciliation
• Reduced exposure to humidity
• Easier dispensing in automated systems

The tradeoff is higher packaging cost and more complex serialization and supply-chain requirements.

International formulation adaptation

Excipient preferences vary by market. A lactose-free tablet, sugar-free liquid, or alcohol-free vehicle can simplify access to markets with restrictive labeling expectations. Preservatives, colorants, and animal-derived excipients may require separate regulatory assessments.

Geographic opportunities are strongest where:

• Prescription antidiarrheal access is established
• Local generic competition is limited
• Pediatric liquid supply is inconsistent
• Hospital procurement values unit-dose packaging
• Controlled-substance distribution can be managed efficiently

Country-specific registration, controlled-drug scheduling, and local reference-product requirements must be assessed before launch.

Lifecycle management through a 505(b)(2) product

A 505(b)(2) product could support a new dosage form or administration benefit that is difficult to capture through an ordinary ANDA. Candidates include an orally disintegrating tablet, a chewable product, a sprinkle formulation, or a ready-to-use single-dose suspension.

The commercial case must justify the added regulatory and manufacturing cost. A new dosage form should solve a concrete problem, such as dysphagia, caregiver dosing, travel use, or institutional administration. A cosmetic reformulation without measurable patient benefit is unlikely to support durable pricing.

How strong is the patent estate for LOMOTIL?

The core patent estate is weak from a generic-entry perspective because diphenoxylate-atropine is an established combination with long-standing market presence and multiple generic competitors.

A new entrant’s defensibility would come from execution and secondary intellectual property:

• Formulation patents
• Device patents
• Process patents
• Trade secrets covering low-dose blending
• Stability data
• Flavor and coating know-how
• Supply agreements
• Trademark and packaging differentiation

Process patents may have value if they solve atropine uniformity or improve yield, but process claims are difficult to enforce when manufacturing occurs offshore or through contract manufacturers. Trade secrets can be more effective where the process is not visible in the finished product.

A formulation patent should be tested against likely design-arounds. Competitors may alter the polymer, sweetener, preservative, particle size, or packaging configuration while retaining similar performance.

What patent litigation and Paragraph IV risks affect a new product?

A conventional diphenoxylate-atropine ANDA may face limited Paragraph IV risk if no relevant unexpired Orange Book patents remain. The principal litigation exposure would arise from any later-listed formulation or device patent associated with a differentiated reference product.

Potential disputes include:

• Certification to a listed formulation patent
• Labeling carve-outs for protected indications
• Bioequivalence failure
• Inactive-ingredient safety concerns
• Patent challenges to a novel taste-masking system
• Trade-secret disputes involving contract manufacturers

A generic applicant should separate the standard tablet program from any novel formulation program. This reduces the risk that a patent dispute or development failure in a differentiated product delays approval of the base product.

How does LOMOTIL compare with loperamide for formulation opportunities?

Attribute	LOMOTIL	Loperamide
Active ingredient	Diphenoxylate plus atropine	Loperamide
Prescription status	Prescription and controlled-substance considerations	Widely available OTC
Core formulation issue	Taste, atropine uniformity, controlled dispensing	Taste, rapid disintegration, pediatric acceptability
Liquid opportunity	Strong	Strong
Abuse and misuse controls	Important	Important because of high-dose misuse concerns
Generic competition	Established	Extensive
Premium opportunity	Pediatric liquid, unit dose, controlled-access packaging	Fast-melt, chewable, liquid, travel formats
Patent basis for differentiation	New formulation or device claims	New formulation, delivery, or packaging claims

LOMOTIL has a narrower but more defensible prescription-channel opportunity. Loperamide has greater retail reach and stronger OTC competition. A LOMOTIL launch should prioritize prescriber and institutional channels rather than attempt to compete directly for mass-market shelf space.

What revenue exposure and launch scenarios exist?

Because LOMOTIL is a mature product, revenue depends on volume, net price, supply reliability, and channel access. A base tablet is likely to face rapid price erosion after multiple generic launches.

Scenario 1: Commodity generic tablet

This is the lowest-risk and lowest-margin route. Success depends on manufacturing cost, FDA approval timing, wholesaler access, and reliable controlled-substance supply.

Scenario 2: Premium oral liquid

A sugar-free, alcohol-free, taste-masked liquid can support higher net pricing if it solves a recognized administration problem. The addressable market is smaller, but competition may be less concentrated than in tablets.

Scenario 3: Institutional unit-dose product

A unit-dose tablet or liquid can win hospital and long-term-care contracts. Contracting cycles are longer, and packaging economics are critical.

Scenario 4: 505(b)(2) specialty dosage form

An ODT, chewable, or multiparticulate product may command the highest price but carries the greatest development and regulatory risk. The product must produce a meaningful administration advantage.

Key Takeaways

• LOMOTIL is a mature diphenoxylate-atropine product with limited value in legacy core patents.
• The principal excipient opportunity is a sugar-free, alcohol-free, taste-masked oral liquid.
• Low-dose atropine creates a significant content-uniformity and segregation challenge.
• Unit-dose packaging can improve controlled-substance accountability and institutional adoption.
• A standard tablet should be developed as a low-risk ANDA platform, separate from any differentiated 505(b)(2) program.
• New patent value would come from formulation, device, packaging, or manufacturing claims rather than the active ingredients.
• Loperamide is the main commercial comparator and has greater OTC reach.
• Generic entry risk is high for an undifferentiated tablet and moderate for a technically differentiated liquid or delivery system.
• Biosimilar risk is irrelevant because LOMOTIL is a small-molecule drug.
• Commercial success depends more on excipient performance, dosing usability, supply reliability, and channel strategy than on exclusivity.

FAQs

Can a lactose-free LOMOTIL tablet be marketed as an ANDA?

Yes, if the formulation remains pharmaceutically equivalent and the inactive ingredients are supported by FDA precedent or an acceptable safety justification. The sponsor must demonstrate bioequivalence and comply with labeling requirements.

Is a sugar-free LOMOTIL liquid commercially differentiated?

Yes. Sugar-free positioning can address diabetes-related concerns, pediatric administration preferences, and institutional formulary requirements. Taste and suspension stability must support the claim in actual use.

Can a new LOMOTIL formulation receive three years of FDA exclusivity?

A 505(b)(2) product may qualify for three-year exclusivity if it contains a new clinical investigation essential to approval. A routine excipient change without qualifying clinical data generally will not create that exclusivity.

What packaging is most suitable for controlled-substance LOMOTIL products?

Unit-dose blisters, foil pouches, and tamper-evident bottles are suitable candidates. The optimal format depends on pharmacy workflow, serialization requirements, moisture protection, and diversion-control procedures.

Is an orally disintegrating LOMOTIL tablet technically feasible?

Yes, but the formulation must address taste, dose uniformity, tablet friability, and rapid disintegration without changing exposure. The atropine content makes blend uniformity a central development risk.

References

1. U.S. Food and Drug Administration. (n.d.). LOMOTIL (diphenoxylate hydrochloride and atropine sulfate) prescribing information. Drugs@FDA.

2. U.S. Drug Enforcement Administration. (n.d.). Controlled substance schedules. U.S. Department of Justice.

3. U.S. Food and Drug Administration. (n.d.). Inactive Ingredient Database. Center for Drug Evaluation and Research.

4. U.S. Food and Drug Administration. (2023). Applications covered by section 505(b)(2). Center for Drug Evaluation and Research.

5. U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations, commonly known as the Orange Book.